{
    "nct_id": "NCT05014776",
    "official_title": "A Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma",
    "inclusion_criteria": "* Age ≥18 years.\n* Have histologically or cytologically proven adenocarcinoma of the pancreas.\n* Have previously treated metastatic disease.\n* Have radiographic disease progression.\n* Patients with the presence of at least one measurable tumor lesion.\n* Patient's acceptance to have a tumor biopsy at baseline and on\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests.\n* For both Women and Men, must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known history or evidence of brain metastases.\n* Had chemotherapy, radiation, or biological cancer therapy within the last 14 days.\n* Have received an investigational agent or device within the last 28 days.\n* Had surgery within the last 28 days.\n* Expected to require any other form of systemic or localized cancer therapy while on study.\n* Have received a vaccine within the last 14 days (7 days for the COVID vaccine) or received a live vaccine within the last 30 days.\n* Have received steroids within the last 14 days.\n* Use more than 4 g/day of acetaminophen.\n* Use of organic nitrates.\n* Use of guanylate cyclase (GC) stimulators such as riociguat.\n* Consumption of substantial amounts of alcohol (≥5 units/day)\n* Use of strong or moderate cytochrome P450 3A4 (CYP3A4) inhibitor or inducer.\n* Patients on immunosuppressive agents within the last 7 days\n* Known allergy to both penicillin and sulfa.\n* Severe hypersensitivity reaction to any monoclonal antibody.\n* History of severe hypersensitivity to tadalafil.\n* Have implant(s) or device(s) that has not and cannot be easily removed.\n* Have artificial joints or implanted medical devices that cannot be easily removed.\n* Have any evidence of clinical or radiographic ascites.\n* Have significant and/or malignant pleural effusion\n* Uncontrolled intercurrent illness.\n* Subjects with active, known or suspected autoimmune disease.\n* Have a tissue or organ allograft, including corneal allograft.\n* Have been diagnosed HIV, Hepatitis B or C positive.\n* Is on supplemental home oxygen.\n* Has an unhealed surgical wound or ulcer, or a bone fracture considered non-healing.\n* Has clinically significant heart disease\n* Prior history of non-arterial ischemic optic retinopathy.\n* History of significant hypotensive episode requiring hospitalization within 6 months.\n* Has insufficient peripheral vein access.\n* Is unwilling or unable to follow the study schedule for any reason.\n* Is pregnant or breastfeeding.",
    "miscellaneous_criteria": ""
}